The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction

Blood Press. 2019 Aug;28(4):215-216. doi: 10.1080/08037051.2019.1625523. Epub 2019 Jun 11.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Aminobutyrates / pharmacology
  • Aminobutyrates / therapeutic use*
  • Angiotensin Receptor Antagonists / therapeutic use
  • Biphenyl Compounds
  • Clinical Trials as Topic
  • Drug Combinations
  • Heart Failure / drug therapy*
  • Heart Failure / mortality
  • Heart Failure / physiopathology
  • Humans
  • Hypertension / drug therapy*
  • Neprilysin / antagonists & inhibitors
  • Stroke Volume
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use*
  • Treatment Outcome
  • Valsartan

Substances

  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination